EUVIMEDEUVIMED entdecken
Crossref

Empagliflozin Reduces High Glucose-Induced Cardiomyopathy in hiPSC-Derived Cardiomyocytes

Hsiu-Hui Tsai, Fu-Chih Hsiao, Alice L Yu, Jyuhn-Huarng Juang, John Yu, Pao-Hsien Chu iD

Stem Cell Reviews and Reports · 2025

DOI: 10.1007/s12015-024-10839-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cell Reviews and Reports, 2025. Verfasst von Hsiu-Hui Tsai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Glucose, Benzhydryl Compounds, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital, Linkou, National Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human-induced pluripotent stem cell (hiPSC) technology has been applied in pathogenesis studies, drug screening, tissue engineering, and stem cell therapy, and patient-specific hiPSC-derived cardiomyocytes (hiPSC-CMs) have shown promise in disease modeling, including diabetic cardiomyopathy. High glucose (HG) treatment induces lipotoxicity in hiPSC-CMs, as evidenced by changes in cell size, beating rate, calcium handling, and lipid accumulation. Empagliflozin, an SGLT2 inhibitor, effectively mitigates the hypertrophic changes, abnormal calcium handling, and contractility impairment induced by HG. Glucose concentration influences SGLT2 expression in cardiomyocytes, highlighting its potential role in diabetic cardiomyopathy. These findings support the potential utility of hiPSC-CMs in studying diabetic cardiomyopathy and the efficacy of empagliflozin in ameliorating HG-induced cardiomyocyte dysfunction. Such research may advance developments in precision medicine and therapeutic interventions for patients with diabetic cardiomyopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacGlucoseBenzhydryl CompoundsInduced Pluripotent Stem CellsGlucosidesDiabetic CardiomyopathiesHumansSodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2Cell Differentiation

Stichwörter der Autor:innen

CardiomyocyteDiabetic cardiomyopathyEmpagliflozinHiPSC

Substanzen

GlucoseempagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Department of Pediatrics, University of California in San Diego, San Diego, CA, USA.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine and Center for Tissue Engineering, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. jjuang@cgmh.org.tw.
  • Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. johnyu@gate.sinica.edu.tw.
  • Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. taipei.chu@gmail.com.

ORCID-Profile: Pao-Hsien Chu

Förderung

  • Chang Gung Memorial Hospital, Linkou
  • National Science and Technology

Zitieren

APA

Tsai, H. H., Hsiao, F. C., Yu, A. L., Juang, J. H., Yu, J., & Chu, P. H. (2025). Empagliflozin Reduces High Glucose-Induced Cardiomyopathy in hiPSC-Derived Cardiomyocytes. Stem Cell Reviews and Reports. https://doi.org/10.1007/s12015-024-10839-8

Vancouver

Tsai HH, Hsiao FC, Yu AL, Juang JH, Yu J, Chu PH. Empagliflozin Reduces High Glucose-Induced Cardiomyopathy in hiPSC-Derived Cardiomyocytes. Stem Cell Reviews and Reports. 2025. doi:10.1007/s12015-024-10839-8

BibTeX
@article{Tsai2025,
  author = {Tsai, Hsiu-Hui and Hsiao, Fu-Chih and Yu, Alice L and Juang, Jyuhn-Huarng and Yu, John and Chu, Pao-Hsien},
  title = {Empagliflozin Reduces High Glucose-Induced Cardiomyopathy in hiPSC-Derived Cardiomyocytes},
  journal = {Stem Cell Reviews and Reports},
  year = {2025},
  doi = {10.1007/s12015-024-10839-8}
}
Kostenlos starten →